Open Payments

DONALD LEE ANDERSON

Type
Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
Where
BANNING, CA
NPI
1447362082
Received
$33,504 in 16 records, 2019 to 2025 ($22 general, $33,481 research)
As principal investigator
$10,506,052 of research payments to others in 838 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024Research payment1$10,534
2023Research payment3$15,428
2022General payment1$22
2022Research payment2$2,028
2019Research payment9$5,491

By company

CompanyRecordsAmountYears
Eli Lilly and Company8$32,1902019–2024
Otsuka Pharmaceutical Development & Commercialization, Inc.7$1,2912019
Boston Scientific Corporation1$222022

By nature of payment

NatureRecordsAmount
Research payment15$33,481
Food and Beverage1$22

Records

DateCompanyAmountNatureFormProductStudyYear
2024-09-24Eli Lilly and Company$10,534Research paymentCash or cash equivalentASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2024
2023-10-10Eli Lilly and Company$14,975Research paymentCash or cash equivalentASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2023
2023-06-08Eli Lilly and Company$153Research paymentIn-kind items and servicesASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2023
2023-01-31Eli Lilly and Company$300Research paymentIn-kind items and servicesA STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2)2023
2022-05-31Boston Scientific Corporation$22Food and BeverageIn-kind items and servicesLUX-Dx Insertable Cardiac Monitor Device, LUX-Dx_CRM2022
2022-05-03Eli Lilly and Company$1,361Research paymentIn-kind items and servicesA PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS 2022
2022-04-29Eli Lilly and Company$667Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2022
2019-10-08Otsuka Pharmaceutical Development & Commercialization, Inc.$217Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-10-08Otsuka Pharmaceutical Development & Commercialization, Inc.$142Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-10-08Otsuka Pharmaceutical Development & Commercialization, Inc.$112Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-10-08Otsuka Pharmaceutical Development & Commercialization, Inc.$50Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-10-08Otsuka Pharmaceutical Development & Commercialization, Inc.$50Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-10-07Otsuka Pharmaceutical Development & Commercialization, Inc.$125Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-10-06Otsuka Pharmaceutical Development & Commercialization, Inc.$593Research paymentIn-kind items and servicesA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB2019
2019-01-28Eli Lilly and Company$1,700Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2019
2019-01-07Eli Lilly and Company$2,500Research paymentCash or cash equivalentASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-18Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$14,790A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-12-11Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$35A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-12-11Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$21,987A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-12-08Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$60A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-12-05Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$1,775A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-11-14Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$30,234A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-11-14Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$105A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-10-27Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$9,681A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-10-17Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$36,948A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-10-17Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$315A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-10-06E.R. Squibb & Sons, L.L.C.ANDERSON CLINICAL RESEARCH$38,940A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar2025
2025-09-29Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,300A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-09-26Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,062A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-09-15Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$20,216A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-09-15Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$48,395A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-09-15Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$4,835A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-09-08ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ANDERSON CLINICAL RESEARCH$11,290A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-09-04Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$15,960A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-09-02ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ANDERSON CLINICAL RESEARCH$60A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-08-26E.R. Squibb & Sons, L.L.C.ANDERSON CLINICAL RESEARCH$1,437A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar2025
2025-08-25Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$60A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-25Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$142A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-25Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$183A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-25Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$232A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-25Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$366A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-18Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$385A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-18Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$60A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-08-18Sage Therapeutics, LLCELLIGO HEALTH RESEARCH INC$1,800A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzhe2025
2025-08-15Eli Lilly and CompanyCLINEDGE LLC$2,045ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2025
2025-08-13Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$40,447A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-08-13Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$140A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-08-04ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ANDERSON CLINICAL RESEARCH$7,382A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2025-07-28Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$60A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-07-23Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$53,023A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-07-23Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$240A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-07-22Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$8,981A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-07-14Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,550A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-07-07Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,955A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-06-30Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,062A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-06-13Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$57,188A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-06-13Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$2,070A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-06-02Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$11,279A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-05-21Biogen, Inc.Elligo Health Research$10,684Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previ2025
2025-05-19Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$183A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-05-16Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$43,469A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-05-16Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$105A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-05-12Eli Lilly and CompanyELLIGO HEALTH RESEARCH INC$97,755ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2025
2025-05-05Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$20,034A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-04-16Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$1,106A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-04-16Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$45,164A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-03-27Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$2,262A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-03-24Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$14,921A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-03-07Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$20,000A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-03-05ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$3,370AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2025
2025-02-28Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$9,813A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-02-25Eli Lilly and CompanyANDERSON CLINICAL RESEARCH$607ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2025-02-18Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$22,814A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-02-14Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$182A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-02-12Eli Lilly and CompanyANDERSON CLINICAL RESEARCH$931ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2025
2025-02-03Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$5,880A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, an2025
2025-01-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$2,180AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2025
2025-01-29ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$19,848AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA2025
2025-01-23ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC$180A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU2025
2025-01-21Eli Lilly and CompanyELLIGO HEALTH RESEARCH INC$13,510ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2025
2025-01-14Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$600A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-01-14Axsome Therapeutics, Inc.ANDERSON CLINICAL RESEARCH$8,688A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2025
2025-01-07ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC$2,800A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2025
2024-12-23Axsome Therapeutics, Inc.Elligo Health Research, Inc.$245A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-12-12Axsome Therapeutics, Inc.Elligo Health Research, Inc.$25,492A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-12-04ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC$500A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2024
2024-11-15Axsome Therapeutics, Inc.Elligo Health Research, Inc.$36,839A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-11-12ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC$1,665A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2024
2024-10-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$50,315A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-10-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$105A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-10-07ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC$3,800A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2024
2024-09-26Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$975A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2024
2024-09-19ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC$4,825A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2024
2024-09-11ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC$19,350A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT2024
2024-09-10Axsome Therapeutics, Inc.Elligo Health Research, Inc.$595A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-09-10Axsome Therapeutics, Inc.Elligo Health Research, Inc.$52,559A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-08-14Axsome Therapeutics, Inc.Elligo Health Research, Inc.$553A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-08-14Axsome Therapeutics, Inc.Elligo Health Research, Inc.$48,767A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-07-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$55,328A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-07-11ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$1,000A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2024
2024-06-20Axsome Therapeutics, Inc.Elligo Health Research, Inc.$80,195A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-06-20Axsome Therapeutics, Inc.Elligo Health Research, Inc.$1,347A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-06-04ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC$7,734A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2024
2024-06-04Eli Lilly and CompanyELLIGO HEALTH RESEARCH INC$71,878ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2024
2024-06-03Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,650A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2024
2024-05-30Otsuka Pharmaceutical Development & Commercialization, Inc.CLINICAL TRIAL SOURCE LLC$2,971A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN2024
2024-05-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$455A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-05-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$81,275A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-05-16ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$416AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2024
2024-05-16ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$416A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2024
2024-05-01ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$17,409A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD2024
2024-04-22Janssen Research & Development, LLCELLIGO HEALTH RESEARCH INC$3,562A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression2024
2024-04-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$70A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-04-16Axsome Therapeutics, Inc.Elligo Health Research, Inc.$59,990A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-03-18Axsome Therapeutics, Inc.Elligo Health Research, Inc.$56,556A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms2024
2024-03-06ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)CLINEDGE LLC$5,267AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Riverside CountyBanning city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Banning, CA, county Riverside County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Banning, CA
County
Riverside County, CA
State
California
Population B0100331,0932,478,60039,287,377
Population, 2020 census P129,5052,418,18539,538,223
Median age B0100242.137.037.9
Under 18 B0100122.8%24.1%22.0%
65 and over B0100127.7%15.4%15.7%
Households B1100111,624775,33513,548,091
Foreign born B0500218.7%21.9%27.0%
Median household income B19013$61,764$93,074$99,122
Median family income B19113$64,695$103,984$113,346
Per capita income B19301$30,856$38,317$49,513
Poverty rate B1700118.8%10.6%12.0%
Unemployment rate B230258.2%6.5%6.6%
Civilian labor force B2302511,5831,191,32320,068,466
Mean commute (minutes) B0801332.633.828.7
Bachelor's degree or higher B1500316.5%25.6%37.1%
Housing units B2500112,355869,41414,644,735
Owner-occupied B2500370.2%69.1%55.9%
Renters B2500329.8%30.9%44.1%
Median home value B25077$352,100$557,300$734,700
Median gross rent B25064$1,650$1,901$2,036
White, not Hispanic B0300233.3%31.0%33.8%
Black B030027.1%6.0%5.2%
Hispanic or Latino B0300250.6%51.3%40.2%
Asian B030025.1%6.9%15.3%
American Indian and Alaska Native B030020.7%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Banning, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.